Suggested remit: To evaluate the benefits and costs of setmelanotide within its marketing authorisation for treating obesity caused by leptin receptor (LEPR) deficiency or pro-opiomelanocortin (POMC) deficiency for national commissioning by NHS England.
Status Proposed
Process HST
ID number 3764

Provisional Schedule

Scoping workshop (Manchester) 31 July 2020 (14:00)

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
08 June 2020 - 06 July 2020 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance